Smischney Nathan J, Williams George, Jabaley Craig S, Khanna Ashish K, Bouldin Bethany, Petrilli Andrew R, Deng Hao, Kinzelman-Vesely Elissa A, Pearl Ronald G
Department of Anesthesiology and Perioperative Medicine, Division of Critical Care Medicine, Mayo Clinic, Rochester, USA.
Department of Anesthesiology, Division of Critical Care Medicine, Memorial Hermann - Texas Medical Center, Houston, USA.
J Intensive Care Med. 2025 May 14:8850666251337702. doi: 10.1177/08850666251337702.
ObjectiveSpecific sedative hypnotic agents, administered to facilitate endotracheal intubation (ETI) in critically ill adults, may lead to adverse outcomes such as peri-intubation cardiovascular collapse. However, little is known from systematic investigations of the impact these individual agents have on cardiovascular function or other clinical outcomes.Data sourcesMEDLINE, Embase, CENTRAL, ClinicalTrials.gov, Scopus and Web of science databases.Study selectionWe conducted a systematic search for randomized and non-randomized studies that evaluated adult (≥18 years) critically ill patients who were sedated to facilitate ETI with ketamine, propofol, ketamine/propofol, etomidate, or a benzodiazepine and who had data on peri-intubation hemodynamics and at least one other outcome involving acute kidney injury, delirium, opioid use, intubation difficulty, sequential organ failure assessment, length of stay, or mortality. Eighty-five studies were identified for eligibility assessment with 23 included in the analysis.Data extractionTwo reviewers independently screened articles, extracted data from selected articles, and assessed risk of bias using ROBINS-I for observational studies and revised Cochrane Risk of Bias tool for randomized controlled trials.Data synthesisAcute cardiovascular dysfunction (peri-intubation hemodynamic instability and/or cardiac arrest) was similar between etomidate and ketamine with more events seen when propofol versus non-propofol sedation was administered. However, exploratory meta-analysis demonstrated no difference between etomidate and ketamine (OR 1.05 [95%CI 0.60-1.84]) or between etomidate and propofol (OR 0.91 [95%CI 0.33-2.46]). Compared to ketamine, etomidate demonstrated lower survival to hospital discharge in the included studies in exploratory meta-analysis OR 0.76 (95%CI 0.62-0.92). Limited data existed for other outcomes with no discernible differences between sedative agents.ConclusionsAcute cardiovascular dysfunction was more common when propofol, as compared to non-propofol sedation, was administered, although not statistically significant in exploratory meta-analysis. In addition, etomidate conferred lower survival to hospital discharge versus non-etomidate sedation, which was confirmed in exploratory meta-analysis of etomidate versus ketamine.
给予特定的镇静催眠药物以促进危重症成年患者的气管插管(ETI),可能会导致诸如插管期间心血管崩溃等不良后果。然而,对于这些个体药物对心血管功能或其他临床结局影响的系统研究却知之甚少。
MEDLINE、Embase、CENTRAL、ClinicalTrials.gov、Scopus和科学网数据库。
我们对随机和非随机研究进行了系统检索,这些研究评估了成年(≥18岁)危重症患者,这些患者接受了氯胺酮、丙泊酚、氯胺酮/丙泊酚、依托咪酯或苯二氮䓬类药物镇静以促进ETI,并且有插管期间血流动力学数据以及至少一项其他结局的数据,这些结局包括急性肾损伤、谵妄、阿片类药物使用、插管困难、序贯器官衰竭评估、住院时间或死亡率。共确定了85项研究进行资格评估,其中23项纳入分析。
两名 reviewers 独立筛选文章,从选定文章中提取数据,并使用ROBINS-I评估观察性研究的偏倚风险,使用修订的Cochrane偏倚风险工具评估随机对照试验的偏倚风险。
依托咪酯和氯胺酮之间的急性心血管功能障碍(插管期间血流动力学不稳定和/或心脏骤停)相似,使用丙泊酚镇静与非丙泊酚镇静相比,出现的事件更多。然而,探索性荟萃分析表明,依托咪酯和氯胺酮之间(比值比1.05 [95%置信区间0.60 - 1.84])或依托咪酯和丙泊酚之间(比值比0.91 [95%置信区间0.33 - 2.46])没有差异。在探索性荟萃分析中,与氯胺酮相比,依托咪酯在纳入研究中显示出院生存率较低,比值比为0.76(95%置信区间0.62 - 0.92)。关于其他结局的数据有限,镇静药物之间没有明显差异。
与非丙泊酚镇静相比,使用丙泊酚时急性心血管功能障碍更常见,尽管在探索性荟萃分析中无统计学意义。此外,与非依托咪酯镇静相比,依托咪酯导致出院生存率较低,这在依托咪酯与氯胺酮的探索性荟萃分析中得到证实。